M2care, a Lyon-based HealthTech venture studio, secured €26 million in funding. The French Tech Accélération 2 (FTA2) fund, managed by Bpifrance, led this investment. Existing investors Mérieux Développement, Institut NAOS des Sciences de la Vie, Crédit Agricole Centre-Est, and Family Offices also participated. This M2care funding healthcare round will accelerate eight new projects.
Founded in 2017 by Mérieux Développement and CEA Investissement, M2care specializes in HealthTech. The studio develops and finances early-stage projects. It connects academics, investors, and industry.
Driving Healthcare Project Development
M2care aims to bring laboratory ideas to market as health products. This benefits public health. The studio has already invested in three projects. These include Previa Medical, TheraSonic, and Rhovica Neuroimaging.
Previa Medical develops a digital device for hospital emergency prediction. TheraSonic creates an ultrasound device for brain diseases. Rhovica Neuroimaging works on a ventricular drainage catheter.
M2care currently advances projects in cardiology, dermatology, ophthalmology, and neurology. A fourth project is launching soon. The FTA2 fund, part of France 2030, has €100 million. It supports startup acceleration structures.
The daily brief
Get the free daily brief with the day's AI news, new AI startups and funding rounds every morning.
Join 64,000 other subscribers.
This strategic M2care funding healthcare investment aims to strengthen France's technological sovereignty. It promotes HealthTech innovation. The funding accelerates technology transfer from academic laboratories to market. This benefits patients directly. Other European VCs like Sofinnova Partners and Karista also invest in similar ventures. M2care's model provides crucial support for complex medical devices.
